Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Citigroup To $47? Plus This Analysts Predict $95 For Papa John's

Published 03/10/2022, 14:12
Updated 03/10/2022, 15:10
© Reuters.  Citigroup To $47? Plus This Analysts Predict $95 For Papa John's

  • Goldman Sachs (NYSE:GS) cut Citigroup Inc. (NYSE: NYSE:C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading.
  • RBC Capital cut The Mosaic Company (NYSE: NYSE:MOS) price target from $85 to $65. Mosaic shares fell 1% to $47.85 in pre-market trading.
  • Morgan Stanley (NYSE:MS) boosted Box, Inc. (NYSE: BOX) price target from $32 to $34. Box shares rose 3.7% to $25.29 in pre-market trading.
  • Mizuho lowered the price target on ALLETE, Inc. (NYSE: ALE) from $58 to $50. ALLETE shares fell 2.3% to close at $50.05 on Friday.
  • Wells Fargo (NYSE:WFC) cut price target for Keurig Dr Pepper Inc. (NASDAQ: NASDAQ:KDP) from $43 to $41. Keurig Dr Pepper shares fell 0.3% to $35.71 in pre-market trading.
  • RBC Capital raised the price target on New Gold Inc. (NYSE: NYSE:NGD) from $1 to $1.25. New Gold shares rose 3% to close at $0.88 on Friday.
  • Wedbush cut the price target for Papa John's International, Inc. (NASDAQ: PZZA) from $109 to $95. Papa John's fell 2.4% to close at $70.01 on Friday.
  • Chardan Capital boosted the price target on Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $62 to $65. Rocket Pharmaceuticals rose 1.8% to $16.25 in pre-market trading.
  • Keybanc reduced the price target on Crown Castle Inc. (NYSE: NYSE:CCI) from $205 to $177. Crown Castle shares rose 0.2% to close at $144.55 on Friday.
  • SVB Leerink cut the price target on Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from $21 to $17. Intercept Pharmaceuticals shares fell 15% to close at $13.95 on Monday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Check out this: Investor Fear Eases Slightly Despite Dow Dipping Around 9% In September

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.